EP1019427A4 - N?6 -substitues-adenosine-5'-uronamides utiles comme modulateurs de recepteurs d'adenosine - Google Patents

N?6 -substitues-adenosine-5'-uronamides utiles comme modulateurs de recepteurs d'adenosine

Info

Publication number
EP1019427A4
EP1019427A4 EP98939156A EP98939156A EP1019427A4 EP 1019427 A4 EP1019427 A4 EP 1019427A4 EP 98939156 A EP98939156 A EP 98939156A EP 98939156 A EP98939156 A EP 98939156A EP 1019427 A4 EP1019427 A4 EP 1019427A4
Authority
EP
European Patent Office
Prior art keywords
adenosine
uronamides
substituted
receptor modulators
adenosine receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98939156A
Other languages
German (de)
English (en)
Other versions
EP1019427A1 (fr
Inventor
Pier G Baraldi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedCo Research Inc
Original Assignee
MedCo Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedCo Research Inc filed Critical MedCo Research Inc
Publication of EP1019427A4 publication Critical patent/EP1019427A4/fr
Publication of EP1019427A1 publication Critical patent/EP1019427A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
EP98939156A 1997-07-29 1998-07-29 N?6 -substitues-adenosine-5'-uronamides utiles comme modulateurs de recepteurs d'adenosine Withdrawn EP1019427A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5406497P 1997-07-29 1997-07-29
US54064P 1997-07-29
PCT/US1998/016053 WO1999006053A1 (fr) 1997-07-29 1998-07-29 N6-substitues-adenosine-5'-uronamides utiles comme modulateurs de recepteurs d'adenosine

Publications (2)

Publication Number Publication Date
EP1019427A4 true EP1019427A4 (fr) 2000-07-19
EP1019427A1 EP1019427A1 (fr) 2000-07-19

Family

ID=21988552

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98939156A Withdrawn EP1019427A1 (fr) 1997-07-29 1998-07-29 N?6 -substitues-adenosine-5'-uronamides utiles comme modulateurs de recepteurs d'adenosine

Country Status (5)

Country Link
EP (1) EP1019427A1 (fr)
JP (1) JP2003517423A (fr)
AU (1) AU8764398A (fr)
CA (1) CA2296485A1 (fr)
WO (1) WO1999006053A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU750322B2 (en) * 1997-05-09 2002-07-18 Trustees Of The University Of Pennsylvania, The Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
YU76100A (sh) 1998-06-02 2003-12-31 Osi Pharmaceuticals Inc. Pirolo(2,3-d) pirimidin preparati i njihova primena
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
KR100840727B1 (ko) 1999-12-02 2008-06-23 오에스아이 파마슈티컬스, 인코포레이티드 아데노신 ａ1, ａ2ａ 및 ａ3 수용체 특이 화합물 및 그의 사용방법
AU2002211142A1 (en) * 2000-10-26 2002-05-06 Actar Ab Screening method using a g coupled receptor associated with a specific g protein
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
JP4012070B2 (ja) * 2001-01-16 2007-11-21 カン−フィテ・バイオファーマ・リミテッド ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
AU2002360436A1 (en) 2001-11-30 2003-06-17 Osi Pharmaceuticals, Inc. 2-aryl pyrrologpyrimidines for a1 and a3 receptors
CN101973998A (zh) 2001-12-20 2011-02-16 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物
CN1620294A (zh) 2001-12-20 2005-05-25 Osi药物公司 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
AU2004284098B2 (en) * 2003-10-21 2009-07-16 Inspire Pharmaceuticals, Inc. Tetrahydro-furo [3,4-d] dioxole compounds and compositions and method for inhibiting platelet aggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
EP1778239B1 (fr) * 2004-07-28 2013-08-21 Can-Fite Biopharma Ltd. Agonistes du recepteur de l'adenosine a3 pour le traitement de troubles de l'oeil sec tels que le syndrome de sjogren
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
EP1798233A1 (fr) * 2005-12-19 2007-06-20 Faust Pharmaceuticals Dérivés de Pyrrolo[1,2-a]quinoxaline et leur utilisation comme modulateurs de recepteurs a l'adenosine
JP5592262B2 (ja) 2007-10-15 2014-09-17 キャン−ファイト・バイオファーマ・リミテッド 肝細胞の増殖を誘導する方法及びその使用
JP5849044B2 (ja) 2009-05-17 2016-01-27 キャン−ファイト バイオファーマ リミテッド 眼圧低下のためのａ３アデノシン受容体作動薬
WO2011010306A1 (fr) 2009-07-21 2011-01-27 Ramot At Tel-Aviv University Ltd. Ligands du récepteur a3 de l’adénosine modulant la pigmentation
MX2012010006A (es) 2010-03-03 2013-01-17 Us Gov Health & Human Serv Agonistas de a3ar para el tratamiento de uveitis.
JP6140825B2 (ja) 2012-08-09 2017-05-31 キャン−ファイト バイオファーマ リミテッドＣａｎ−Ｆｉｔｅ ＢｉｏＰｈａｒｍａ Ｌｔｄ． 性機能不全の治療に使用するためのａ３アデノシン受容体リガンド
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
IL254535A0 (en) 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
IL264112A (en) 2019-01-06 2020-07-30 Fishman Pnina An a3 adenosine receptor ligand for use for reducing level of adipocytes
IT202300014340A1 (it) 2023-07-10 2025-01-10 Consiglio Nazionale Ricerche Trattamento di malattie associate alla disfunzione del gene ocrl.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050047A1 (fr) * 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methodes visant a reduire une lesion ischemique cardiaque par administration d'agonistes et d'antagonistes du recepteur d'adenosine et compositions afferentes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310731A (en) * 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050047A1 (fr) * 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methodes visant a reduire une lesion ischemique cardiaque par administration d'agonistes et d'antagonistes du recepteur d'adenosine et compositions afferentes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C.GALLO-RODRIGUEZ ET AL.: "Structure Activity Relationships of N6-Benzyladenosine-5'-uronamides as A3 Selective Adenosine Agonists.", JOURNAL OF MEDICINAL CHEMISTRY., vol. 37, no. 5, 4 March 1994 (1994-03-04), AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, pages 636 - 646, XP002136400, ISSN: 0022-2623 *
H.O.KIM ET AL.: "2-Substitution of N6-Benzoyladenosine-5'-Uronamides Enhances Selectivity for A3 Adenosine Receptors.", JOURNAL OF MEDICINAL CHEMISTRY., vol. 37, no. 21, 14 October 1994 (1994-10-14), AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, pages 3614 - 3621, XP002136401, ISSN: 0022-2623 *
JACOBSON ET AL.: "Adenosine Receptors: Pharmacology, Structure-Activity Relationships, and Therapeutic Potential", JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, no. 3, 1992, pages 407 - 423 *
See also references of WO9906053A1 *

Also Published As

Publication number Publication date
EP1019427A1 (fr) 2000-07-19
WO1999006053A1 (fr) 1999-02-11
CA2296485A1 (fr) 1999-02-11
JP2003517423A (ja) 2003-05-27
AU8764398A (en) 1999-02-22

Similar Documents

Publication Publication Date Title
EP1019427A4 (fr) N?6 -substitues-adenosine-5'-uronamides utiles comme modulateurs de recepteurs d'adenosine
GB2353527B (en) Adenosine A3 receptor modulators
HUP0100536A3 (en) Fiber distributor
GB9715751D0 (en) Formulations
SG82568A1 (en) Ink compositions
HU9601529D0 (en) Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists
IL133920A0 (en) Trail receptor
AU7132898A (en) Edg-1-like receptor
GB9517098D0 (en) Receptor
GB9617923D0 (en) Novel receptor
AUPO938697A0 (en) Novel receptor
GB2321753B (en) Metering system
PL340723A1 (en) Structural member
GB9701050D0 (en) Structural member
ZA987267B (en) Nucleosides
GB9710434D0 (en) Distributor units
GB9515669D0 (en) Releasable fixing means
PL320747A1 (en) Novel receptor
IL156851A0 (en) Adenosine a3 receptor modulators
IL139493A0 (en) Adenosine a3 receptor modulators
GB9703676D0 (en) Stable system
HU0002453D0 (en) Novel nucleosides
CA81596S (en) Structural member
AU133746S (en) Distributor
AUPO910797A0 (en) Receptor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000202

A4 Supplementary search report drawn up and despatched

Effective date: 20000606

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010330

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011010